Argenica Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGN.AX research report →
Price Chart
About the company
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
- CEO
- Liz Dallimore
- IPO
- 2021
- Employees
- 7
- HQ
- Nedlands, WA, AU
Get TickerSpark's AI analysis on AGN.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.05M
- P/E
- -2.56
- Fwd P/E
- 0.94
- PEG
- 0.05
- P/S
- 65.94
- P/B
- 7.27
- EV/EBITDA
- -4.41
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2832.32%
- Net Margin
- -2579.83%
- ROE
- -183.51%
- ROIC
- -312.47%
Latest fiscal year · YoY change
- Revenue
- $3.21M+23.7%
- Gross Profit
- $3.21M+23.7%
- Op Income
- $-7,682,594
- Net Income
- $-7,170,347-30.9%
- EPS
- $-0.06-6.0%
- OCF Growth
- -12.7%
- FCF Growth
- -12.7%
- 52W High
- $0.72
- 52W Low
- $0.09
- 50D MA
- $0.14
- 200D MA
- $0.20
- Beta
- 0.76
- RSI (14)
- 62
- Avg Volume
- 335.08K
No earnings-call transcripts are available for AGN.AX yet.
- Free Float
- 75.4%
- Shares Outstanding
- 128.46M
- Float Shares
- 96.89M
Our AGN.AX coverage
Recent articles, reports, and earnings notes.
No research on AGN.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGN.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.